The Nasdaq Composite (IXIC) has been on a rollercoaster ride as 2025 draws to a close, experiencing a notable three-day losing streak before showing a modest rebound on December 17. This recent volatility has ignited discussions around an "AI bubble" and raised questions about the sustainability of the tech sector's
December S&P 500 E-Mini futures (ESZ25) are trending up +0.27% this morning as investors continue to digest the latest U.S. jobs data, while also awaiting remarks from Federal Reserve officials and an earnings report from semiconductor giant Micron.
Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately -
over the past six months, healthcare stocks have gained 14.1%, nearly mirrorring the S&P 500.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Large trillion-dollar companies are tightening their grip on the market, often by acquiring smaller rivals.
This trend will likely pick up with new regulatory leadership, but a few mid-sized businesses will continue prospering by anchoring themselves in unique market segments.
Stay updated with the movements of the S&P500 index in the middle of the day on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
CNSide Diagnostics, a Plus Therapeutics subsidiary, secured a national agreement with Humana to provide its CNSide CSF Tumor Cell Enumeration test, expanding coverage to 67 million people.
President Donald Trump continues to take aim at major health insurance companies and says he only supports sending money to individuals, not subsidies for insurance companies.
UnitedHealth shares dipped earlier this week as Trump’s populist healthcare remarks rattled insurers, but fundamentals and long-term guidance may tell a more resilient story.
